Samsara BioCapital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Samsara BioCapital’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-689,709	Closed	-$160K	–	47
2024 Q3	$160K	Hold	689,709	–	–	0.03%	37
2024 Q2	$375K	Hold	689,709	–	–	0.08%	35
2024 Q1	$704K	Hold	689,709	–	–	0.11%	34
2023 Q4	$393K	Hold	689,709	–	–	0.06%	36
2023 Q3	$717K	Hold	689,709	–	–	0.22%	35
2023 Q2	$972K	Hold	689,709	–	–	0.17%	38
2023 Q1	$1.1M	Hold	689,709	–	–	0.23%	41
2022 Q4	$1.01M	Hold	689,709	–	–	0.22%	39
2022 Q3	$2.94M	Hold	689,709	–	–	0.69%	30
2022 Q2	$2.68M	Sell	689,709 -21,330	-3%	-$60.8K	0.71%	30
2022 Q1	$3.38M	Hold	711,039	–	–	0.85%	29
2021 Q4	$2.6M	Hold	711,039	–	–	0.5%	32
2021 Q3	$5.7M	Hold	711,039	–	–	0.89%	26
2021 Q2	$8.06M	Sell	711,039 -120,586	-15%	-$1.21M	1%	20
2021 Q1	$7.69M	Buy	+831,625	New	+$8.66M	1.42%	19
2020 Q2	–	Sell	-169,663	Closed	-$2.46M	–	36
2020 Q1	$2.46M	Hold	169,663	–	–	1.42%	19
2019 Q4	$2M	Buy	169,663 +66,494	+64%	+$1.11M	0.96%	18
2019 Q3	$2.6M	Buy	103,169 +42,857	+71%	+$1.24M	1.77%	12
2019 Q2	$1.53M	Sell	60,312 -46,831	-44%	-$1.81M	1.01%	15
2019 Q1	$4.56M	Buy	+107,143	New	+$2.43M	3.58%	9

Other funds holding VIRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital's VIRX Position: Q4 2024 in Review

Samsara BioCapital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 689,709 shares — an estimated $160K sold.

Samsara BioCapital first reported a position in VIRX in Q1 2019 and held it in 20 quarters. The position peaked at $8.06M in Q2 2021. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.

Samsara BioCapital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Samsara BioCapital sold 689,709 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $160K.
Samsara BioCapital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
Samsara BioCapital's Viracta Therapeutics, Inc. Common Stock position peaked at $8.06M in Q2 2021.
32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Samsara BioCapital's 13F filing for Q4 2024, filed 14 Feb 2025.